Abstract
Hepatitis D virus (HDV), also referred to as hepatitis delta virus, is the smallest virus capable of causing human disease. It is unable to replicate on its own and can only propagate in the presence of hepatitis B virus (HBV). Infection with both HBV and HDV frequently results in more severe disease than HBV alone, with higher instances of cirrhosis, liver failure and hepatocellular carcinoma (HCC). Thus, there is a need for effective treatment for HDV; however, currently approved treatment options are very limited both in terms of their efficacy and availability. This makes the management of HDV a challenge for physicians. In this review, we look at the background, diagnosis and treatment of HDV, informed by our hospital data, to set out the optimal management of HDV; we also explore novel treatment options for this disease.
| Original language | English |
|---|---|
| Pages (from-to) | 1-6 |
| Number of pages | 6 |
| Journal | Clinical Medicine, Journal of the Royal College of Physicians of London |
| Volume | 23 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Jul 2023 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:© Royal College of Physicians 2023.
Keywords
- Hepatitis D virus
- bulevirtide
- lonafarnib
- nucleic acid polymer REP 2139
- pegylated interferon
